Next-generation CAR T-cell therapies represent a paradigm shift in cancer immunotherapy, integrating synthetic biology and logic-gated designs to enhance precision, safety, and efficacy. This chapter delves into the advancements of CAR T-cell engineering, where synthetic biology has enabled the creation of sophisticated systems that reprogram T-cells for improved functionality and reduced off-target effects. Logic-gated CARs incorporate AND, OR, and NOT gate designs, ensuring tumor-specific activation by requiring multiple antigen inputs or avoiding healthy tissue markers. These innovations aim to address the limitations of traditional CAR T-cells, including antigen escape, tumor heterogeneity, and systemic toxicity. The chapter explores the mechanisms behind synthetic gene circuits, multi-antigen targeting strategies, and safety switches that allow precise control over CAR T-cell activity. Advances in incorporating Boolean logic, combinatorial antigen recognition, and checkpoint inhibitor integration are discussed, alongside real-world preclinical and clinical applications. Emerging tools such as Clustered regularly interspaced short palindromic repeats (CRISPR) gene editing and programmable synthetic pathways further amplify the effectiveness of CAR T-cells. By focusing on the human impact, this chapter highlights how next-generation CARs minimize side effects, enhance therapeutic response, and expand treatment options for solid and hematologic malignancies. Challenges related to manufacturing, scalability, and regulatory compliance are critically analyzed, paving the way for future innovations that align synthetic biology with clinical needs to revolutionize cancer care.